Clinicopathological Study of Oral Malignant and Premalignant Lesions with p53 and p16 Immunostaining

Authors

  • Debashis Chakrabarty Asso. Prof. Department of Pathology, Institute of Postgraduate Medical Education & Research (IPGME&R), Kolkata
  • Riju Bhattacharya Department of Pathology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India
  • Srijita Mridha Department of Pathology, Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India

DOI:

https://doi.org/10.37591/rrjooh.v8i2.1596

Abstract

Oral cancer is a global problem, more in India. A study of 50 cases of oral lesions were conducted in a tertiary care hospital in Kolkata, India. Detailed clinical history was taken. Cytology, punch biopsy with histopathology and immunostaining with p53 and p16 were done in all the cases. A total of 31 cases (62.0%) were benign, 19 cases (38.0%) were malignant, with an age range of 26–69 years (mean age 47.7 years). Cytology, histology and immunostains correlated well. p53 and p16 both showed high scoring in malignant lesions and significant p-values.

 

Keywords: brush cytology, toluidine blue, histopathology, immunostaining

Cite this Article

Bhattacharya R, Chakrabarty D, Mridha S. Clinicopathological Study of Oral Malignant and Premalignant Lesions with p53 and p16 Immunostaining. Research & Reviews: Journal of Oncology and Hematology. 2019; 8(2): 20–24p.

Downloads

Published

2019-07-16

Issue

Vol. 8 No. 2 (2019)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.